Precision BioSciences Set for Breakout with Key Gene Editing Trials
AI Prediction of Precision BioSciences, Inc. (DTIL)
Precision BioSciences, a clinical stage gene editing company, is positioned for potential share price appreciation with upcoming clinical catalysts. The company's focus on gene-editing therapies for high unmet needs, specifically its PBGENE-HBV and PBGENE-DMD programs, offers significant upside potential.
Precision BioSciences is actively developing its proprietary ARCUS genome editing platform to create in vivo gene editing therapies targeting diseases with high unmet needs. Key programs include PBGENE-HBV for chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. Both programs are approaching significant clinical milestones, with expected data readouts that could serve as major catalysts for the stock. The company's strategic focus on these diseases, combined with a robust clinical development pipeline and a strong cash position to support operations through 2028, positions Precision BioSciences as a compelling investment in the biotech sector. These factors are expected to significantly influence the company's stock price in the near term.
DTIL Report Information
Prediction Date2026-03-23
Close @ Prediction$6.52
Mkt Cap222m
IPO DateN/a
AI-derived Information
Recent News for DTIL
- Jul 14, 8:47 am — Laboratory Operations and Technology Innovator Chris Clendening Joins Precision for Medicine to Lead Specialty Labs (PRNewswire RSS)
- Jul 10, 7:01 am — Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
- Jul 7, 4:15 pm — Flyte Partners with LifeVac to Equip Every Vision Jet with Life-Saving Equipment (GlobeNewswire RSS)
- Jul 6, 8:00 am — Catheter Precision, Inc. Announces Issuance of Two Key Patents (GlobeNewswire RSS)
- Jul 2, 8:00 am — Flyte Announces Successful Launch of New Direct-to-Consumer Booking Platform (GlobeNewswire RSS)
- Jun 29, 7:01 am — Precision BioSciences Announces Inclusion in the Russell 2000 Index Expanding Market Visibility with Institutional Investors (Business Wire)
- Jun 23, 11:23 am — WPI Expands NanoFil™ Family with New Syringe Sizes for Ultra-Low-Volume Delivery (PRNewswire RSS)
- Jun 22, 4:15 pm — Flyte Partners with GSE Worldwide and PGA TOUR Professional Emiliano Grillo, Debuted at the 2026 U.S. Open (GlobeNewswire RSS)
- Jun 22, 8:41 am — Precision Production Appoints Rick Sykora to Chief Financial Officer (PRNewswire RSS)
- Jun 22, 8:00 am — Catheter Precision, Inc. Announces Allowance of Key Intellectual Property (GlobeNewswire RSS)
- Jun 17, 8:54 am — Precision Neuroscience™ Wins 2026 Webby Award; Earns Back-to-Back Fast Company World Changing Ideas Honor (GlobeNewswire RSS)
- Jun 17, 8:31 am — Pinnacera Precision Launches to Unite Driv-Lok and WCS Industries (PRNewswire RSS)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest